Market Overview:
Bronchiectasis is a chronic lung disease characterized by damage to the airways of the lungs which results in a build-up of excess mucus within the lungs. Some of the major symptoms of bronchiectasis include chronic cough, excessive phlegm production, weight loss, fatigue and recurring respiratory infections. Drugs to treat bronchiectasis aim to control or prevent exacerbations, loosen and thin out mucus, treat infections and improve symptoms and lung function. The major classes of drugs used for bronchiectasis treatment include bronchodilators, antibiotics, expectorants, anti-inflammatory drugs and mucolytics.
Market key trends:
One of the key trends in the bronchiectasis drugs market is the emergence and development of advanced therapies for treating lung conditions. Companies are increasingly investing in R&D to develop newer biologics and targeted therapies with novel mechanisms of action. For instance, Insmed is developing Amikacin liposome inhalation suspension, an antibiotic developed using Lipid Amikacin Pulmonary Technology for chronic lung diseases including nontuberculous mycobacterial lung disease and bronchiectasis infection. Another therapy under development is Arbaviral, an antiviral nanobody being developed by Arbor Pharmaceuticals as an inhaled therapy for viral exacerbations in patients with lung diseases like cystic fibrosis or bronchiectasis. Such advanced lung-targeted therapies have potential to provide better treatment outcomes and improve quality of life of patients compared to conventional therapies.
Porter's Analysis
Threat of new entrants: Low barrier of entry in terms of technology but high costs associated with R&D and regulatory requirements pose challenges to new entrants.
Bargaining power of buyers: Large pharmaceutical players have strong bargaining power over drug manufacturers due to availability of alternative treatment options and pricing pressures to reduce health care costs.
Bargaining power of suppliers: Suppliers of raw materials including active pharmaceutical ingredients have moderate bargaining power due to availability of substitutes and established supply relationships of major players.
Threat of new substitutes: Threat from new alternative treatment options remains high due to ongoing research in developing novel therapeutics.
Competitive rivalry: Intense due to presence of many global and local players offering generic and branded drugs.
The global Bronchiectasis Drugs Market Demand is estimated to be valued at US$ 303.8 Mn in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Key Takeaways
The global Bronchiectasis Drugs market is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing prevalence of chronic respiratory diseases and launch of novel combination therapies.
Regionally, North America is expected to dominate the Bronchiectasis Drugs market owing to sizeable patient population, favourable reimbursement policies, and presence of key pharma players. However, Asia Pacific is anticipated to exhibit fastest growth during the forecast period, driven by expanding healthcare infrastructure, large patient demography, and growing medical tourism in China and India.
Key players operating in the Bronchiectasis Drugs market are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Sanofi S.A., Sunovion Pharmaceuticals Inc., Mylan N.V., Cipla Ltd., Grifols S.A., Insmed Incorporated, Arbor Pharmaceuticals LLC. Major players are focusing on new product launches and acquisitions to strengthen their market position.
For more insights, read-
https://www.marketwebjournal.com/bronchiectasis-drugs-market-market-size-and-share-analysis/
Herbal Treatment for Bronchiectasis also helps to loosen mucus in the lungs.
Herbal Remedies for Bronchiectasis can prevent damage to the lungs and improve symptoms.
